BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.680
-0.320 (-16.00%)
At close: Jun 13, 2025, 4:00 PM
1.660
-0.020 (-1.19%)
After-hours: Jun 13, 2025, 7:55 PM EDT
BioRestorative Therapies Revenue
BioRestorative Therapies had revenue of $25.00K in the quarter ending March 31, 2025, a decrease of -28.57%. This brings the company's revenue in the last twelve months to $391.00K, up 161.54% year-over-year. In the year 2024, BioRestorative Therapies had annual revenue of $401.00K with 175.03% growth.
Revenue (ttm)
$391.00K
Revenue Growth
+161.54%
P/S Ratio
35.17
Revenue / Employee
$35,545
Employees
11
Market Cap
12.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
| Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
| Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
| Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
| Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BRTX News
- 16 hours ago - BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease - GlobeNewsWire
- 4 days ago - BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 - GlobeNewsWire
- 4 weeks ago - BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - GlobeNewsWire
- 5 weeks ago - BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - GlobeNewsWire
- 5 weeks ago - BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - GlobeNewsWire
- 2 months ago - BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - GlobeNewsWire
- 2 months ago - BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States - GlobeNewsWire